Changes in lipid profiles after switching to a protease inhibitor-containing cART - unfavourable effect of fosamprenavir in obese patients

European Journal of Medical Research

U Seybold¹  JR Bogner¹  M Gyalrong-Steur¹ 

[1]Infektionsabteilung der Medizinischen Poliklinik, Campus Innenstadt, Ludwig-Maximilians-Universität, München, Germany

关键词: statistical interaction;    multivariate linear regression;    cardiovascular risk;    obesity;    dyslipidemia;    body mass index;    metabolism;    glucose;    triglycerides;    cholesterol;    lipids;    saquinavir;    fosamprenavir;    atazanavir;    protease inhibitor;    cART;    HIV;   

Others  :  828354
DOI  :  10.1186\2047-783X-16-2-85

 received in 2010-11-01, accepted in 2010-11-01,  发布年份 2011

【 摘 要 】

Objective

One focus in the medical care of HIV-infected patients today is cardiovascular risk reduction. Metabolic disturbances occur frequently in patients taking protease inhibitors (PI) and are a major risk factor for atherosclerosis. With few published head-to head studies substance-specific differences concerning metabolic effects are insufficiently defined. Therefore this cohort study directly compared the metabolic profiles of boosted atazanavir (ATV/r), fosamprenavir (FPV/r) and saquinavir (SQV/r).

Methods

Data from a cohort of 124 HIV patients initiating a boosted regimen with one of the PIs at the University of Munich (LMU) infectious diseases outpatient clinic were retrospectively analyzed. The main outcome measures were median absolute total cholesterol levels and median relative change of total cholesterol levels after six months of PI-therapy. A multivariate linear regression model was built to identify and control for potential confounders of the association between PI-therapy and serum cholesterol level.

Results

84 patients were treated with ATV/r, 23 patients received FPV/r and 17 patients SQV/r. Demographically the cohort constituted a representative sample of HIV-infected patients in Germany. There were no statistically significant differences between the comparison groups at baseline.

After six months of therapy median serum cholesterol in the ATV/r group dropped significantly from 204 mg/dl to 186 mg/dl, while in the FPV/r and SQV/r groups a rise in serum cholesterol levels was observed from 179 mg/dl to 204 mg/dl and from 173 mg/ddl to 209 mg/dl respectively. The multivariate linear regression model identified a significant interaction between BMI at baseline and treatment with FPV/r: patients with higher BMI showed more prominent increases in serum cholesterol while taking FPV/r compared to patients with lower BMI.

Conclusion

This cohort study demonstrated the most favourable impact on serum cholesterol levels and thus cardiovascular risk for ATV/r compared to FPV/r and SQV/r under real-life conditions. Given the statistical interaction detected between FPV/r and BMI further studies assessing metabolic profiles of different antiretroviral drugs in specific patient populations are urgently needed.

【 授权许可】

   
2011 I. Holzapfel Publishers

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Assmann G, Schulte H, Cullen P, Seedorf U: Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. European Journal of Clinical Investigation 2007, 37(12):925-32.
• [2]Conroy RM, Pyorala K, Fitzgerald AP, et al.: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal 2003, 24(11):987-1003.
• [3]Graham I, Atar D, Borch-Johnsen K, et al.: European guidelines on cardiovascular disease prevention in clinical practice: executive summary. European Heart Journal 2007, 28(19):2375-414.
• [4]Adult Treatment Panel III: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Paneflll). JAMA 2001, 285(19):2486-97.
• [5]Lloyd-Jones DM, Wilson PWF, Larson MG, et al.: Lifetime Risk of Coronary Heart Disease by Cholesterol Levels at Selected Ages. Archives of Internal Medicine 2003, 163(16):1966-72.
• [6]Bhargava A: A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study. Popul Health Metr 2003, 1(3):1-16.
• [7]Greenland P, Knoll MD, Stamler J, et al.: Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events. JAMA Vol. 290: Am Med Assoc 2003, 891-7.
• [8]Lewington S, Whitlock G, Clarke R, et al.: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370(9602):1829-39.
• [9]Niederlaender E: Causes of death in the EU. A report by the EU's statistical office, Eurostat European Communities 2006.
• [10]Kung HC, Hoyert DL, Xu J, Murphy SL: Deaths: final data for 2005. Natl Vital Stat Rep 2008, 56(10):1-120.
• [11]Bundesamt S: Todesursachen - Sterbefalle insgesamt 2007 nach den 10 haufigsten Todesursachen. [http:/ / www.destatis.de/ jetspeed/ portal/ cms/ Sites/ destatis/ Internet/ DE/ Content/ Statistiken/ Gesundheit/ Todesursachen/ Tabellen/ Content75/ SterbefaelleInsgesamt,templateId=re nderPrint.psml] webcite 2008. Last access on August 22
• [12]Bundesamt S: Todesursachen in Deutschland - Gestor- bene in Deutschland an ausgewahlten Todesursachen - 2006. Statistisches Bundesamt 2006.
• [13]Detels R, Munoz A, McFarlane G, et al.: Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998, 280(17):1497-503.
• [14]Bhaskaran K, Hamouda O, Sannes M, et al.: Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008, 300(1):51-9.
• [15]Lewden C, May T, Rosenthal E, et al.: Causes de décès en France en 2005 des adultes infectées par le VIH et évolution par rapport à 2000. Bulletin épidémiologique hebdomadaire 2006 2006, (48):379-82.
• [16]Palella FJ, Baker RK, Moorman AC, et al.: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43(1):27-34.
• [17]Crum NF, Riffenburgh RH, Wegner S, et al.: Comparisons of causes of death and mortality rates among HIV- infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006, 41(2):194-200.
• [18]El-Sadr WM, Lundgren JD, Neaton JD, et al.: CD4+ Count-guided interruption of antiretroviral treatment. New England Journal of Medicine 2006, 355(22):2283-96.
• [19]Phillips AN, Carr A, Neuhaus J, et al.: Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008, 13(2):177-87.
• [20]Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74(5):1045-52.
• [21]Neumann T, Miller M, Esser S, Gerken G, Erbel R: Arteriosklerose bei HIV-positiven Patienten. Zeitschrift für Kardiologie 2002, 91(11):879-88.
• [22]Friis-Moller N, Weber R, Reiss P, et al.: Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS 2003, 17(8):1179-93.
• [23]Friis-Moller N, Sabin CA, Weber R, et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349(21):1993-2003.
• [24]Fellay J, Boubaker K, Ledergerber B, et al.: Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001, 358(9290):1322-7.
• [25]Friis-Moller N, Reiss P, Sabin CA, et al.: Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356(17):1723-35.
• [26]Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366(9493):1267-78.
• [27]Lundgren JD, Battegay M, Mallon P, et al.: European AIDS Clinical Society (EACS) guidelines: Prevention and management of non-infectious co-morbidities in HIV, version 5. [http:/ / wwweuropeanaidsclinicalsocietyorg/ guideline-spdf/ 2_Non_Infectious_Co_Morbidities_in_ HIVpdf] webcite 2009. Last access on May 3, 2010
• [28]Clumeck N, Dedes N, Pozniak A, Raffi F: the EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults, version 5. [http://www.europeanaidsclinicalsociety.org/Guidelines/index.htm] webcite 2009. last access on Sept. 6, 2010
• [29]Centers for Disease Control and Prevention. About BMI for Adults. Healthy Weight [http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html] webcite 2009. Last access on January 27, 2010
• [30]Thompson MA, Aberg JA, Cahn P, et al.: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304(3):321-33.
• [31]Deutsche AIDS Gesellschaft, Österreichische AIDS Gesellschaft [http:/ / www.daignet.de/ site-content/ hiv-therapie/ leitlin ien-1/ resolveuid/ 4e09c351567524bfd215f4d46a9b6f5a] webciteDeutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-1-InfektionLast access on September 9, 2010
• [32]Purnell JQ, Zambon A, Knopp RH, et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14(1):51-7.
• [33]Sullivan AK, Nelson MR: Marked hyperlipidaemia on ritonavir therapy. AIDS 1997, 11(7):938-9.
• [34]Martinez E, Domingo P, Galindo MJ, et al.: Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004, 38(7):1017-23.
• [35]Walmsley S, Bernstein B, King M, et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002, 346(26):2039-46.
• [36]Dube MP, Stein JH, Aberg JA, et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37(5):613-27.
• [37]Tsiodras S, Mantzoros C, Hammer S, Samore M: Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000, 160(13):2050-6.
• [38]Periard D, Telenti A, Sudre P, et al.: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999, 100(7):700-5.
• [39]Fontas E, van Leth F, Sabin CA, et al.: Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004, 189(6):1056-74.
• [40]Lee GA, Seneviratne T, Noor MA, et al.: The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004, 18(4):641-9.
• [41]Lafeuillade A, Hittinger G, Philip G, Lambry V, Jolly P, Poggi C: Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra). HIV Clinical Trials 2004, 5(6):392-8.
• [42]Gatell J, Salmon-Ceron D, Lazzarin A, et al.: Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007, 44(11):1484-92.
• [43]Molina JM, Andrade-Villanueva J, Echevarria J, et al.: Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008, 372(9639):646-55.
• [44]Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al.: Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005, 39(2):174-80.
• [45]Cahn PE, Gatell JM, Squires K, et al.: Atazanavir-a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic Ill) 2004, 3(3):92-8.
• [46]Segerer S, Bogner JR, Walli R, Loch O, Goebel FD: Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999, 27(2):77-81.
• [47]Dragsted UB, Gerstoft J, Pedersen C, et al.: Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis 2003, 188(5):635-42.
• [48]Dragsted UB, Gerstoft J, Youle M, et al.: A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther 2005, 10(6):735-43.
• [49]Manfredi R, Chiodo F: Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect 2001, 42(3):181-8.
• [50]Eron J, Yeni P, Gathe J, et al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomized non-inferiority trial. Lancet 2006, 368(9534):476-82.
• [51]Gathe JC, Ive P, Wood R, et al.: SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004, 18(11):1529-37.
• [52]Smith KY, Weinberg WG, Dejesus E, et al.: Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008, 5:5. BioMed Central Full Text
• [53]European Society of Cardiology [http://www.heartscore.org/Pages/welcome.aspx] webciteHeartScore Programme 2009. Last access on February 27, 2010
• [54]De Backer G, Ambrosioni E, Borch-Johnsen K, et al.: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal 2003, 24(17):1601-10.
• [55]Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109(3):433-8.
• [56]Alberti KG, Zimmet P, Shaw J: The metabolic syndrome- -a new worldwide definition. Lancet 2005, 366(9491):1059-62.
• [57]Johnson M, Grinsztejn B, Rodriguez C, et al.: Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005, 19(7):685-94.
• [58]Johnson M, Grinsztejn B, Rodriguez C, et al.: 96-week comparison of once-daily atazanavir/ritonavir and twice daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006, 20(5):711-8.
• [59]Mallolas J, Podzamczer D, Milinkovic A, et al.: Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART the ATAZIP study. J Acquir Immune Defic Syndr 2009, 51(1):29-36.
• [60]Wood R, Phanuphak P, Cahn P, et al.: Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004, 36(2):684-92.
• [61]Rodriguez-French A, Boghossian J, Gray GE, et al.: The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004, 35(1):22-32.
• [62]Robert Koch-Institut: HIV/AIDS in Deutschland -Eckdaten, Epidemiologische Kurzinformation des Robert Koch-Instituts, Stand: Ende. [http:/ / www.rki.de/ cln_100/ nn_195960/ DE/ Content/ InfAZ/ H/ HIVAIDS/ Epidemiologie/ Daten_und_Ber ichte/ EckdatenDeutschland,templateId=raw, property=publicationFile.pdf/ EckdatenDeutschland.pdf] webcite 2008. Last access on June 30, 2009
• [63]Institute for Pharmacogenomics and Individualized Therapy [http://www.ipit.unc.edu/] webciteHomepage of the Institute for Pharmacogenomics and Individualized Therapy 2007. Last access on December 10, 2009
• [64]Hauner H, Buchholz G, Hamann B, Koletzko B: Prävention und Therapie der Adipositas - Evidenzbasierte Leitlinie Version 2007. 2007.
• [65]Gesundheitsberichtserstattung des Bundes. Cholesterinmesswerte im Bundes-Gesundheitssurvey 1998 in Deutschland [http:/ / www.gbe-bund.de/ gbe10/ abrechnung.prc_abr_test_logon?p_uid =gastg&p_aid=&p_knoten=FID&p_sp rac he=D&p_suchstring=4228::Cholesterin] webcite Last access on May 20, 2009
• [66]Gesundheitsberichtserstattung des Bundes [http:/ / www.gbe-bund.de/ gbe10/ abrechnung.prc_abr_test_logon?p_uid =gastg&p_aid=&p_knoten=FID&p_sprach e=D&p_suchstring=8397::Body-Mass-In dex] webciteBody Mass Index (BMI) der erwachsenen Bevölkerung 1998. Last access on August 30, 2009
• [67]Gesundheitsberichtserstattung des Bundes [http:/ / www.gbe-bund.de/ gbe10/ abrechnung.prc_abr_test_logon?p_uid =gastg&p_aid=&p_knoten=FID&p_sprach e=D&p_suchstring=10700::Hypertonie] webciteBluthoch- druck - Gesundheit in Deutschland 2006. Last access on August 30, 2009
• [68]Diabetes Deutschland. Diabetes: Themen und Fakten - Die aktuelle Situation [http://www.diabetes-deutschland.de/aktuellesituation.html] webciteDiabetes: Themen und Fakten 2007. Last access on August 30, 2009